MedTrace Logo

ATATcH Alternating Treatment Plans for Advanced Cancer

NCT05358548 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-04-30

No results posted yet for this study

Summary

The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.

Conditions

Interventions

DRUG

Paclitaxel

Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor

DRUG

Pemetrexed

Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor

DRUG

5Fluorouracil

Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor

DRUG

Carboplatin

Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor

DRUG

Pembrolizumab

It is a type of immunotherapy and works by helping your immune system to kill cancer cells

Sponsors & Collaborators

  • Rutgers, The State University of New Jersey

    lead OTHER

Principal Investigators

  • Missak Haigentz, MD · Rutgers Cancer Institute of New Jersey

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-28
Primary Completion
2027-05-01
Completion
2028-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05358548 on ClinicalTrials.gov